Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Peritoneal mesothelioma.

Faheez Mohamed1, Paul H Sugarbaker

  • 1The Washington Cancer Institute, Washington Hospital Center, 110 Irving Street, NW, Suite CG-185, Washington, DC 20010, USA.

Current Treatment Options in Oncology
|August 27, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Morphology and Pathophysiology of 10 Different Types of Peritoneal Metastases.

Journal of surgical oncology·2026
Same author

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy can be safely combined with nephrectomy in patients with appendiceal malignancy and synchronous renal cell carcinoma.

Journal of surgical case reports·2026
Same author

Assessment of Outcome in 198 Patients With Mucinous Appendiceal Adenocarcinoma and Peritoneal Metastases Over 25 Years.

Journal of surgical oncology·2026
Same author

Response to Letter Comments on Raised Serum Tumor Markers Predict Incomplete Cytoreduction, Disease-Free and Overall Survival in Patients with Colorectal Peritoneal Metastases Treated by Cytoreductive Surgery and HIPEC.

Annals of surgical oncology·2026
Same author

ASO Visual Abstract: MORPHology and Inter-Observer Variation in Peritoneal Disease Assessment Among Expert Peritoneal Malignancy SUrgeonS-The MORPHEUS Study.

Annals of surgical oncology·2026
Same author

Correction: MORPHology and Inter-observer Variation in Peritoneal Disease Assessment Among Expert Peritoneal Malignancy SUrgeonS: The MORPHEUS study.

Annals of surgical oncology·2026

Malignant peritoneal mesothelioma, a rare cancer, is now treatable with a multimodality approach. This strategy combines cytoreductive surgery with intraperitoneal chemotherapy, significantly improving survival and quality of life for patients.

Area of Science:

  • Oncology
  • Surgical Oncology
  • Medical Oncology

Background:

  • Peritoneal mesothelioma is a rare, aggressive malignancy with poor prognosis and limited treatment options.
  • Intravenous chemotherapy has shown unsatisfactory results for this disease.
  • The localized nature of peritoneal mesothelioma suggests regional therapy as a promising approach.

Purpose of the Study:

  • To define the natural history, diagnosis, and management of peritoneal mesothelioma.
  • To evaluate the efficacy of intraperitoneal chemotherapy in combination with cytoreductive surgery.
  • To explore treatment strategies for improving patient survival and quality of life.

Main Methods:

  • Cytoreductive surgery followed by heated intraoperative intraperitoneal chemotherapy (HIPEC) with cisplatin and doxorubicin.

Related Experiment Videos

  • Early postoperative intraperitoneal paclitaxel administration.
  • Adjuvant intraperitoneal paclitaxel and second-look cytoreduction procedures.

    • Main Results:

    • The multimodality treatment approach has extended median survival to 50–60 months.
    • High complete response rates are observed, as confirmed by negative second-look assessments.
    • Prolonged disease-free survival and reduced adverse symptoms have been documented.

    Conclusions:

    • Malignant peritoneal mesothelioma, considered an orphan disease, is treatable with a combination of debulking surgery and intraperitoneal chemotherapy.
    • This approach offers potential cure for a subset of patients diagnosed and treated early.
    • A prolonged, high quality of life is achievable for the majority of patients receiving this treatment.